Rituximab in the treatment of anti-SRP antibody positive immune-mediated necrotizing myositis: a review of 5 cases
10.3760/cma.j.cn141217-20240318-00091
- VernacularTitle:利妥昔单抗治疗抗信号识别颗粒自身抗体阳性免疫介导坏死性肌炎5例分析
- Author:
Dehua ZHAO
1
;
Ye TIAN
;
Lu ZHANG
;
Chunjia LI
Author Information
1. 中日友好医院风湿免疫科，北京 100029
- Keywords:
Myositis;
Anti signal recognition-particle autoantibody;
Rituximab
- From:
Chinese Journal of Rheumatology
2024;28(10):728-732
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the therapeutic response and safety of rituximab in patients with anti-SRP antibody positive immune-mediated necrotizing myositis.Methods:We identified five patients with anti-SRP antibody positive immune-mediated necrotizing myositis who received rituximab treatment in the rheumatology and immunology department of China-Japan Friendship Hospital from March 2022 to October 2023, and reviewed their clinical characteristics, treatment response to rituximab and adverse reaction.Results:After 6 months of treatment with rituximab, 3 of 5 patients were effective and all were significantly effective, 1 patient showed no response, 1 patient died of "pulmonary infection" after 5 months of treatment, and 1 patient developed latent tuberculosis infection.Conclusion:Rituximab is effective in the treatment of anti-SRP antibody positive immune-mediated necrotizing myositis,with a low incidence of adverse reactions and overall benefits outweighing risks.
